NCT02645734

Trial name or title	The Effect of Bevacizumab and Ziv‐aflibercept in Diabetic Macular Edema
Methods	Parallel group RCT
Participants	DMO participants
Interventions	Active comparator: injection intravitreous bevacizumab Active comparator: injection ziv‐aflibercept at dose of 1.25 mg Active comparator: injection ziv‐aflibercept at dose of 2.5 mg
Outcomes	Primary outcome measures: VA (time frame: until 6 months) Secondary outcome measures: CSFT (time frame: until 6 months)
Starting date	Study first received: 2 January 2016 Last updated: 4 January 2016 Estimated primary completion date: February 2016 (final data collection date for primary outcome measure)
Contact information	Zahra Rabbani Khah, Shahid Beheshti Medical University
Notes	This study is recruiting participants; (status checked on ClinicalTrials.gov on 5 December 2016)